A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
This study is testing a new medicine called etavopivat for people living with sickle cell disease. The main goal is to find out if etavopivat can reduce the number of painful events called vaso-occlusive crises (VOCs), which happen when blood vessels get blocked. We also want to see if this medicine can lessen damage to organs, help people exercise more easily, and reduce feelings of tiredness. Half of the participants will receive etavopivat, and the other half will receive a 'dummy pill' (placebo). Who gets which treatment is decided by chance. This study is expected to last for about two years and is part of the ongoing research into etavopivat.
Auf einen Blick
Worum geht es in dieser Studie?
This study is investigating a new medicine called etavopivat for people with sickle cell disease. Sickle cell disease is a lifelong condition that can cause severe pain and other serious health problems. These painful episodes are often called 'crises' or Vaso-occlusive crises (VOCs). They happen when the sickle-shaped red blood cells block small blood vessels, stopping blood from reaching parts of the body. This study wants to see if etavopivat can help reduce how often these painful crises occur.
Beyond reducing pain crises, the research team is also looking at other important aspects of living with sickle cell disease. They want to understand if etavopivat can help protect different organs in the body from the damage that can happen over time with this condition. They will also check if the medicine improves how well people can exercise and whether it reduces the common feeling of extreme tiredness, known as fatigue, that many people with sickle cell disease experience.
Overall, the aim is to confirm if etavopivat is a safe and effective treatment that could improve the lives of adults and teenagers with sickle cell disease. The study will compare etavopivat to a 'placebo', which is a dummy medicine with no active ingredients, to clearly see the effects of the new treatment.
Wichtige Erkenntnisse
- This study is testing a new medicine called etavopivat for sickle cell disease.
- It aims to reduce painful crises, protect organs, and lessen tiredness.
- Participants will receive either etavopivat or a dummy pill (placebo) by chance.
- The study involves regular clinic visits and health checks over about two years.
- If you have sickle cell and are aged 12 or older, you might be able to join.
- Sie können die Teilnahme jederzeit beenden, ohne dass dies Ihre medizinische Versorgung beeinträchtigt.
Wer könnte berechtigt sein?
To join this study, you need to be at least 12 years old, male or female, and have been diagnosed with sickle cell disease. This diagnosis needs to be confirmed by past medical tests like a blood test (haemoglobin electrophoresis or HPLC). You must also have experienced between 1 and 15 painful sickle cell crises (VOCs) in the 12 months before the study starts. These crises need to be recorded in your medical notes, not just remembered.
Your blood test results at the start of the study (called 'screening') also need to show that your haemoglobin levels are somewhere between 5.0 and 10.0 grams per decilitre. This helps ensure that the medicine is being tested in people who fit certain medical criteria for the study.
There are also some reasons why you couldn't take part. For example, if you've had more than 15 painful crises in the last year, or if you're currently having regular blood transfusions. Also, if you use certain other medicines for sickle cell disease, like voxelotor or crizanlizumab, you might not be able to join, or you might need to stop them a certain amount of time before starting the study.
Könnte diese Studie für Sie geeignet sein?
Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.
- Sind Sie 12 Jahre alt oder älter?
- Do you have a confirmed diagnosis of sickle cell disease?
- Have you had between 1 and 15 painful sickle cell crises (VOCs) in the last year, documented by a doctor?
- Are you NOT currently receiving regular, planned blood transfusions?
- Are you NOT currently taking certain other specific sickle cell medicines?
- Is your haemoglobin level, as measured by a doctor, between 5.0 and 10.0 g/dL?
Was beinhaltet die Teilnahme?
If you decide to take part in this study, you'll either receive the new medicine, etavopivat, or a dummy pill (placebo). Which one you get will be decided by chance, like flipping a coin. You won't know which one you're receiving, and neither will your study doctor. This is to make sure the results are fair.
Throughout the study, you'll have regular visits to the clinic where the study team will monitor your health, ask about your symptoms (like pain crises and tiredness), and perform tests. These tests might include blood samples and checks on how well your organs are working. They'll also check your exercise ability. The total study duration is expected to be about two years, involving ongoing treatment and follow-up during this time.
Potenzielle Risiken und Vorteile
Standorte (175)
- Uni of Alabama at BirminghamVerifizierte PostleitzahlBirmingham, Vereinigte Staaten· Rekrutierung
- Univer South Alabama Ped/OncVerifizierte PostleitzahlMobile, Vereinigte Staaten· Rekrutierung
- Phoenix Children's HsptlVerifizierte PostleitzahlPhoenix, Vereinigte Staaten· Rekrutierung
- Arkansas Children's HospitalVerifizierte PostleitzahlLittle Rock, Vereinigte Staaten· Rekrutierung
- Children's Hospital Los Angeles - EndocrinologyVerifizierte PostleitzahlLos Angeles, Vereinigte Staaten· Rekrutierung
- UCLA HealthVerifizierte PostleitzahlLos Angeles, Vereinigte Staaten· Abgeschlossen
- Valley Children's HospitalVerifizierte PostleitzahlMadera, United States· Rekrutierung
- University Of California IrvineVerifizierte PostleitzahlOrange, Vereinigte Staaten· Abgeschlossen
- Stanford University_Palo AltoVerifizierte PostleitzahlPalo Alto, Vereinigte Staaten· Rekrutierung
- Harbor-UCLA Medical CenterVerifizierte PostleitzahlTorrance, Vereinigte Staaten· Rekrutierung
- Clinical and Transl Res CenterVerifizierte PostleitzahlAurora, Vereinigte Staaten· Abgeschlossen
- Nemours/AI duPont Hosp-ChldVerifizierte PostleitzahlWilmington, Vereinigte Staaten· Rekrutierung
Häufige Fragen
What is etavopivat?
Etavopivat is a new medicine being tested to see if it helps people with sickle cell disease by possibly reducing painful crises and improving other symptoms.
Was ist ein 'Placebo'?
A placebo is a 'dummy' pill that looks like the study medicine but doesn't contain any active ingredients. It's used to compare the real medicine's effects.
Wie lange wird die Studie dauern?
The study is expected to last for about two years for each participant.
Werde ich wissen, ob ich das echte Medikament oder das Placebo erhalte?
No, neither you nor your study doctor will know whether you are receiving etavopivat or the placebo. This helps ensure fair and accurate study results.
Will taking part in this study change my regular medical care?
Participating in the study shouldn't stop you from receiving your usual care, but some treatments might need to be paused or adjusted during the study. This will be discussed in detail.
Wie Sie mehr erfahren können
Novo Nordisk
Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.
Interessiert daran, teilzunehmen?
Diskussion
Community-Diskussion
Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.